Pseudomonas aeruginosa (P. aeruginosa) represents an important bacterial pathogen, mainly because it may infect immunocompromised hosts, hospital patients, and people with cystic fibrosis (CF). Antimicrobial resistance has risen due to monitoring nosocomial P. aeruginosa infections, with tendencies toward model drug and carbapenem resistance. Some of the mechanisms of antimicrobial resistance include the downregulation of outer membrane porins, -lactamases, and multidrug efflux pumps. Toxins that be secreted and can build BioFlim (BF) are examples of virulence mechanisms. Effective therapy of infection caused by P. aeruginosa requires early delivery of the appropriate antibiotic medications, source control measures, and, where possible, prevention. Antibacterial de-escalation is supposed to be considered within patients by a positive clinical response, particularly as antibacterial susceptibilities were identified. Less common antibacterials, including Colistin, may be needed to treat multidrug-resistant P. aeruginosa, although additional anti-pseudomonal antibacterials should become accessible soon.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.